Serveur d'exploration sur les peptides biopesticides

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

N(G)-monomethyl-L-arginine alters insulin-mediated calf blood flow but not glucose disposal in the elderly.

Identifieur interne : 003A02 ( Main/Exploration ); précédent : 003A01; suivant : 003A03

N(G)-monomethyl-L-arginine alters insulin-mediated calf blood flow but not glucose disposal in the elderly.

Auteurs : G S Meneilly [Canada] ; T. Elliott ; B. Battistini ; J S Floras

Source :

RBID : pubmed:11230783

Descripteurs français

English descriptors

Abstract

It has been proposed that an important component of glucose disposal is insulin-mediated vasodilation via a nitric oxide (NO)-dependent mechanism. Normal aging is characterized by a resistance to insulin-mediated glucose disposal and deficient endothelial NO production. Impairment of insulin-mediated vasodilation could contribute to this insulin resistance. We tested the hypothesis that the NO synthase inhibitor N(G)-monomethyl-L-arginine (L-NMMA) would decrease insulin-mediated calf vasodilation and whole-body glucose disposal in young subjects but would have little or no effect in the elderly. Experiments were performed on healthy young (n = 10) and old (n = 10) subjects on 2 study days. Insulin was infused for 4 hours at 40 mU/m(2)/min (young) and 34 mU/m(2)/min (old) during both studies, and L-NMMA (0.1 mg/kg/min) was coinfused during the last 2 hours of insulin on one of these sessions. Calf blood flow was measured by venous occlusion plethysmography, and calf vascular conductance was derived from calf blood flow and mean arterial blood pressure (MABP). L-NMMA increased whole-body insulin-mediated glucose uptake (IMGU) in young subjects (from 11.22 +/- 0.08 to 12.22 +/- 0.87 mg/kg/min, P <.05) but decreased calf blood flow (from 6.53 +/- 0.62 to 5.49 +/- 0.43 mL/100 mL/min, P <.05). In contrast, L-NMMA had no effect on IMGU in elderly subjects (control v L-NMMA, 7.58 +/- 0.46 v 7.86 +/- 0.37 mg/kg/min, P = nonsignificant) but increased calf blood flow (from 3.65 +/- 0.36 to 4.50 +/- 0.32 mL/100 mL/min, P <.01). L-NMMA decreased calf vascular conductance in young subjects (from 0.083 +/- 0.008 to 0.064 +/- 0.005 mL/100 mL/min/mm Hg, P <.05) but not in the elderly (control v L-NMMA, 0.038 +/- 0.004 v 0.040 +/- 0.002 mL/100 mL/min/mm Hg), consistent with the concept that skeletal muscle endothelial NO production is reduced with age. We therefore conclude that (1) L-NMMA has different or opposite actions on calf blood flow and IMGU in both age groups, indicating that the effect of insulin on skeletal muscle blood flow is independent of its influence on glucose disposal in young and old, and (2) skeletal muscle NO production decreases with age.

DOI: 10.1053/meta.2001.19493
PubMed: 11230783


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">N(G)-monomethyl-L-arginine alters insulin-mediated calf blood flow but not glucose disposal in the elderly.</title>
<author>
<name sortKey="Meneilly, G S" sort="Meneilly, G S" uniqKey="Meneilly G" first="G S" last="Meneilly">G S Meneilly</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
<orgName type="university">Université de la Colombie-Britannique</orgName>
<placeName>
<settlement type="city">Vancouver</settlement>
<region type="state">Colombie-Britannique </region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Elliott, T" sort="Elliott, T" uniqKey="Elliott T" first="T" last="Elliott">T. Elliott</name>
</author>
<author>
<name sortKey="Battistini, B" sort="Battistini, B" uniqKey="Battistini B" first="B" last="Battistini">B. Battistini</name>
</author>
<author>
<name sortKey="Floras, J S" sort="Floras, J S" uniqKey="Floras J" first="J S" last="Floras">J S Floras</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2001">2001</date>
<idno type="RBID">pubmed:11230783</idno>
<idno type="pmid">11230783</idno>
<idno type="doi">10.1053/meta.2001.19493</idno>
<idno type="wicri:Area/Main/Corpus">003A94</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">003A94</idno>
<idno type="wicri:Area/Main/Curation">003A94</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">003A94</idno>
<idno type="wicri:Area/Main/Exploration">003A94</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">N(G)-monomethyl-L-arginine alters insulin-mediated calf blood flow but not glucose disposal in the elderly.</title>
<author>
<name sortKey="Meneilly, G S" sort="Meneilly, G S" uniqKey="Meneilly G" first="G S" last="Meneilly">G S Meneilly</name>
<affiliation wicri:level="4">
<nlm:affiliation>Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, University of British Columbia, Vancouver, British Columbia</wicri:regionArea>
<orgName type="university">Université de la Colombie-Britannique</orgName>
<placeName>
<settlement type="city">Vancouver</settlement>
<region type="state">Colombie-Britannique </region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Elliott, T" sort="Elliott, T" uniqKey="Elliott T" first="T" last="Elliott">T. Elliott</name>
</author>
<author>
<name sortKey="Battistini, B" sort="Battistini, B" uniqKey="Battistini B" first="B" last="Battistini">B. Battistini</name>
</author>
<author>
<name sortKey="Floras, J S" sort="Floras, J S" uniqKey="Floras J" first="J S" last="Floras">J S Floras</name>
</author>
</analytic>
<series>
<title level="j">Metabolism: clinical and experimental</title>
<idno type="ISSN">0026-0495</idno>
<imprint>
<date when="2001" type="published">2001</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Aging (metabolism)</term>
<term>Aging (physiology)</term>
<term>Biological Availability (MeSH)</term>
<term>Blood Glucose (analysis)</term>
<term>Blood Pressure (drug effects)</term>
<term>Enzyme Inhibitors (pharmacology)</term>
<term>Female (MeSH)</term>
<term>Glucose (metabolism)</term>
<term>Humans (MeSH)</term>
<term>Hypoglycemic Agents (pharmacology)</term>
<term>Insulin (blood)</term>
<term>Insulin (pharmacology)</term>
<term>Leg (blood supply)</term>
<term>Male (MeSH)</term>
<term>Muscle, Skeletal (metabolism)</term>
<term>Reference Values (MeSH)</term>
<term>Regional Blood Flow (drug effects)</term>
<term>Vascular Resistance (drug effects)</term>
<term>omega-N-Methylarginine (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte (MeSH)</term>
<term>Antienzymes (pharmacologie)</term>
<term>Biodisponibilité (MeSH)</term>
<term>Débit sanguin régional (effets des médicaments et des substances chimiques)</term>
<term>Femelle (MeSH)</term>
<term>Glucose (métabolisme)</term>
<term>Glycémie (analyse)</term>
<term>Humains (MeSH)</term>
<term>Hypoglycémiants (pharmacologie)</term>
<term>Insuline (pharmacologie)</term>
<term>Insuline (sang)</term>
<term>Jambe (vascularisation)</term>
<term>Muscles squelettiques (métabolisme)</term>
<term>Mâle (MeSH)</term>
<term>Pression sanguine (effets des médicaments et des substances chimiques)</term>
<term>Résistance vasculaire (effets des médicaments et des substances chimiques)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Valeurs de référence (MeSH)</term>
<term>Vieillissement (métabolisme)</term>
<term>Vieillissement (physiologie)</term>
<term>oméga-N-Méthylarginine (pharmacologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en">
<term>Blood Glucose</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Insulin</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr">
<term>Glycémie</term>
</keywords>
<keywords scheme="MESH" qualifier="blood supply" xml:lang="en">
<term>Leg</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Blood Pressure</term>
<term>Regional Blood Flow</term>
<term>Vascular Resistance</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Débit sanguin régional</term>
<term>Pression sanguine</term>
<term>Résistance vasculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Aging</term>
<term>Glucose</term>
<term>Muscle, Skeletal</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Glucose</term>
<term>Muscles squelettiques</term>
<term>Vieillissement</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antienzymes</term>
<term>Hypoglycémiants</term>
<term>Insuline</term>
<term>oméga-N-Méthylarginine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Enzyme Inhibitors</term>
<term>Hypoglycemic Agents</term>
<term>Insulin</term>
<term>omega-N-Methylarginine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Vieillissement</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Aging</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr">
<term>Insuline</term>
</keywords>
<keywords scheme="MESH" qualifier="vascularisation" xml:lang="fr">
<term>Jambe</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Biological Availability</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Reference Values</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Biodisponibilité</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Valeurs de référence</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">It has been proposed that an important component of glucose disposal is insulin-mediated vasodilation via a nitric oxide (NO)-dependent mechanism. Normal aging is characterized by a resistance to insulin-mediated glucose disposal and deficient endothelial NO production. Impairment of insulin-mediated vasodilation could contribute to this insulin resistance. We tested the hypothesis that the NO synthase inhibitor N(G)-monomethyl-L-arginine (L-NMMA) would decrease insulin-mediated calf vasodilation and whole-body glucose disposal in young subjects but would have little or no effect in the elderly. Experiments were performed on healthy young (n = 10) and old (n = 10) subjects on 2 study days. Insulin was infused for 4 hours at 40 mU/m(2)/min (young) and 34 mU/m(2)/min (old) during both studies, and L-NMMA (0.1 mg/kg/min) was coinfused during the last 2 hours of insulin on one of these sessions. Calf blood flow was measured by venous occlusion plethysmography, and calf vascular conductance was derived from calf blood flow and mean arterial blood pressure (MABP). L-NMMA increased whole-body insulin-mediated glucose uptake (IMGU) in young subjects (from 11.22 +/- 0.08 to 12.22 +/- 0.87 mg/kg/min, P <.05) but decreased calf blood flow (from 6.53 +/- 0.62 to 5.49 +/- 0.43 mL/100 mL/min, P <.05). In contrast, L-NMMA had no effect on IMGU in elderly subjects (control v L-NMMA, 7.58 +/- 0.46 v 7.86 +/- 0.37 mg/kg/min, P = nonsignificant) but increased calf blood flow (from 3.65 +/- 0.36 to 4.50 +/- 0.32 mL/100 mL/min, P <.01). L-NMMA decreased calf vascular conductance in young subjects (from 0.083 +/- 0.008 to 0.064 +/- 0.005 mL/100 mL/min/mm Hg, P <.05) but not in the elderly (control v L-NMMA, 0.038 +/- 0.004 v 0.040 +/- 0.002 mL/100 mL/min/mm Hg), consistent with the concept that skeletal muscle endothelial NO production is reduced with age. We therefore conclude that (1) L-NMMA has different or opposite actions on calf blood flow and IMGU in both age groups, indicating that the effect of insulin on skeletal muscle blood flow is independent of its influence on glucose disposal in young and old, and (2) skeletal muscle NO production decreases with age.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">11230783</PMID>
<DateCompleted>
<Year>2001</Year>
<Month>04</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0026-0495</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>50</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2001</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Metabolism: clinical and experimental</Title>
<ISOAbbreviation>Metabolism</ISOAbbreviation>
</Journal>
<ArticleTitle>N(G)-monomethyl-L-arginine alters insulin-mediated calf blood flow but not glucose disposal in the elderly.</ArticleTitle>
<Pagination>
<MedlinePgn>306-10</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>It has been proposed that an important component of glucose disposal is insulin-mediated vasodilation via a nitric oxide (NO)-dependent mechanism. Normal aging is characterized by a resistance to insulin-mediated glucose disposal and deficient endothelial NO production. Impairment of insulin-mediated vasodilation could contribute to this insulin resistance. We tested the hypothesis that the NO synthase inhibitor N(G)-monomethyl-L-arginine (L-NMMA) would decrease insulin-mediated calf vasodilation and whole-body glucose disposal in young subjects but would have little or no effect in the elderly. Experiments were performed on healthy young (n = 10) and old (n = 10) subjects on 2 study days. Insulin was infused for 4 hours at 40 mU/m(2)/min (young) and 34 mU/m(2)/min (old) during both studies, and L-NMMA (0.1 mg/kg/min) was coinfused during the last 2 hours of insulin on one of these sessions. Calf blood flow was measured by venous occlusion plethysmography, and calf vascular conductance was derived from calf blood flow and mean arterial blood pressure (MABP). L-NMMA increased whole-body insulin-mediated glucose uptake (IMGU) in young subjects (from 11.22 +/- 0.08 to 12.22 +/- 0.87 mg/kg/min, P <.05) but decreased calf blood flow (from 6.53 +/- 0.62 to 5.49 +/- 0.43 mL/100 mL/min, P <.05). In contrast, L-NMMA had no effect on IMGU in elderly subjects (control v L-NMMA, 7.58 +/- 0.46 v 7.86 +/- 0.37 mg/kg/min, P = nonsignificant) but increased calf blood flow (from 3.65 +/- 0.36 to 4.50 +/- 0.32 mL/100 mL/min, P <.01). L-NMMA decreased calf vascular conductance in young subjects (from 0.083 +/- 0.008 to 0.064 +/- 0.005 mL/100 mL/min/mm Hg, P <.05) but not in the elderly (control v L-NMMA, 0.038 +/- 0.004 v 0.040 +/- 0.002 mL/100 mL/min/mm Hg), consistent with the concept that skeletal muscle endothelial NO production is reduced with age. We therefore conclude that (1) L-NMMA has different or opposite actions on calf blood flow and IMGU in both age groups, indicating that the effect of insulin on skeletal muscle blood flow is independent of its influence on glucose disposal in young and old, and (2) skeletal muscle NO production decreases with age.</AbstractText>
<CopyrightInformation>Copyright 2001 by W.B. Saunders Company</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Meneilly</LastName>
<ForeName>G S</ForeName>
<Initials>GS</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Elliott</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Battistini</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Floras</LastName>
<ForeName>J S</ForeName>
<Initials>JS</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Metabolism</MedlineTA>
<NlmUniqueID>0375267</NlmUniqueID>
<ISSNLinking>0026-0495</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007328">Insulin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>27JT06E6GR</RegistryNumber>
<NameOfSubstance UI="D019323">omega-N-Methylarginine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>IY9XDZ35W2</RegistryNumber>
<NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007866" MajorTopicYN="N">Leg</DescriptorName>
<QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014655" MajorTopicYN="N">Vascular Resistance</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019323" MajorTopicYN="N">omega-N-Methylarginine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2001</Year>
<Month>3</Month>
<Day>7</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2001</Year>
<Month>4</Month>
<Day>6</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2001</Year>
<Month>3</Month>
<Day>7</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">11230783</ArticleId>
<ArticleId IdType="pii">S0026-0495(01)49203-1</ArticleId>
<ArticleId IdType="doi">10.1053/meta.2001.19493</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
<region>
<li>Colombie-Britannique </li>
</region>
<settlement>
<li>Vancouver</li>
</settlement>
<orgName>
<li>Université de la Colombie-Britannique</li>
</orgName>
</list>
<tree>
<noCountry>
<name sortKey="Battistini, B" sort="Battistini, B" uniqKey="Battistini B" first="B" last="Battistini">B. Battistini</name>
<name sortKey="Elliott, T" sort="Elliott, T" uniqKey="Elliott T" first="T" last="Elliott">T. Elliott</name>
<name sortKey="Floras, J S" sort="Floras, J S" uniqKey="Floras J" first="J S" last="Floras">J S Floras</name>
</noCountry>
<country name="Canada">
<region name="Colombie-Britannique ">
<name sortKey="Meneilly, G S" sort="Meneilly, G S" uniqKey="Meneilly G" first="G S" last="Meneilly">G S Meneilly</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A02 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A02 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    BiopestPeptidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:11230783
   |texte=   N(G)-monomethyl-L-arginine alters insulin-mediated calf blood flow but not glucose disposal in the elderly.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:11230783" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a BiopestPeptidV1 

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 19:22:35 2020. Site generation: Thu Nov 19 19:33:26 2020